ClinicalTrials.Veeva

Menu
V

VA Greater Los Angeles Healthcare System | West Los Angeles VA Medical Center - Cardiology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Enzalutamide
Docetaxel
Selonsertib
Rucaparib
Copper Cu 64
Darusentan
Ralinepag
Apixaban
Acetylcysteine
Olpasiran

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 72 total trials

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) st...

Enrolling
Hypertension
Familial Primary Pulmonary Hypertension
Drug: Ralinepag
Drug: Placebo

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Ph...

Invitation-only
Hypertension
Familial Primary Pulmonary Hypertension
Drug: Ralinepag

The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombi...

Active, not recruiting
Metastatic Castration Resistant Prostate Cancer
Drug: Abiraterone acetate or Enzalutamide or Docetaxel
Drug: Rucaparib

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfa...

Enrolling
Prostate Adenocarcinoma
Prostate Cancer
Drug: Copper Cu 64 PSMA I&T

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate c...

Enrolling
Biochemical Recurrence of Malignant Neoplasm of Prostate
Prostate Adenocarcinoma
Drug: Copper Cu 64 PSMA I&T

The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when use...

Active, not recruiting
Pulmonary Arterial Hypertension
Device: Model 10642 Implantable Intravascular Catheter

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipi...

Active, not recruiting
Stroke
Myocardial Infarction
Drug: Evolocumab
Drug: Routine Lipid Management
Locations recently updated

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). The dose optimization Phase 2 part will be investigating the safe...

Enrolling
Metastatic Castration-resistant Prostate Cancer
Drug: FPI-2265

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-met...

Active, not recruiting
Adenocarcinoma of the Prostate
Biological: sipuleucel-T

Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate can...

Not yet enrolling
Prostate Cancer Diagnosis
Drug: 18F- DCFPyl Injection
Diagnostic Test: PSMA PET scan

The purpose of this study is to evaluate the efficacy and safety of \[Lu-177\]-PNT2002 in patients with metastatic castration-resistant prostate canc...

Active, not recruiting
Metastatic Castration-Resistant Prostate Cancer
Drug: Enzalutamide
Drug: Abiraterone

This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in comb...

Active, not recruiting
Metastatic Prostate Cancer
Castration-resistant Prostate Cancer
Drug: I-131-1095
Drug: Enzalutamide

This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenousl...

Enrolling
mCRPC
Metastatic Castration-resistant Prostate Cancer
Biological: INKmune

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling
Cancer
Drug: Darolutamide (Nubeqa, BAY1841788)

Trial sponsors

US Department of Veterans Affairs (VA) logo
V
Gilead Sciences logo
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
University of California, Los Angeles (UCLA) logo
Amgen logo
Bayer logo
C
Medtronic logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems